ArcticZymes AS has a long history dating back to the late 1980’s with its foundation firmly planted in the fishing industry of Northern Norway. In the mid-1990’s Biotec Pharmacon acquired the technology for production of Shrimp Alkaline Phosphatase and built a department for production of molecular grade enzymes. In June 2009 Biotec Pharmacon created ArcticZymes, a 96% owned subsidiary. Biotec Pharmacon ASA is noted on the Oslo Stock Exchange under the BIOTEC ticker symbol.
ArcticZymes has a rich history in the ability to leverage its access to the marine Arctic; identify novel cold-adapted enzymes for us in molecular research and diagnostics, manufacture, and commercialize our enzyme portfolio.